The Unlikely Development of CAR T Cells: a Brief History and Prospects for the Future.

IF 1.1 Q4 MEDICINE, RESEARCH & EXPERIMENTAL KEIO JOURNAL OF MEDICINE Pub Date : 2023-01-01 DOI:10.2302/kjm.ABSTRACT_72_1-1
Carl H June
{"title":"The Unlikely Development of CAR T Cells: a Brief History and Prospects for the Future.","authors":"Carl H June","doi":"10.2302/kjm.ABSTRACT_72_1-1","DOIUrl":null,"url":null,"abstract":"<p><p>The quest to cure cancer has been one of the Holy Grails of medicine. The discovery I am going to share with you, CAR T cells, is a promising new form of therapy of cancer that offers the prospect of curing cancer using the immune system. CAR T cells are the first form of synthetic biology to enter the practice of medicine. The notion of using the immune system to fight cancer is an old idea. Over a century ago, bacteria were ground up and injected into patients with late-stage cancers, and occasionally the cancer would disappear. However, we now have precise tools for genetic editing and gene insertion like CRISPR/Cas9 to rewrite the DNA code, offering the possibility to improve the immune system over what has evolved in a Darwinian fashion. In 2017 for the first time, CAR T cells were approved for the treatment of cancer. Today they are used worldwide in more than 15,000 patients and they offer the promise to move beyond cancer to other fields of medicine such as autoimmune disease and heart disease. Here I will discuss the promises and challenges faced by the evolving CAR T cell industry.</p>","PeriodicalId":46245,"journal":{"name":"KEIO JOURNAL OF MEDICINE","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"KEIO JOURNAL OF MEDICINE","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2302/kjm.ABSTRACT_72_1-1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

The quest to cure cancer has been one of the Holy Grails of medicine. The discovery I am going to share with you, CAR T cells, is a promising new form of therapy of cancer that offers the prospect of curing cancer using the immune system. CAR T cells are the first form of synthetic biology to enter the practice of medicine. The notion of using the immune system to fight cancer is an old idea. Over a century ago, bacteria were ground up and injected into patients with late-stage cancers, and occasionally the cancer would disappear. However, we now have precise tools for genetic editing and gene insertion like CRISPR/Cas9 to rewrite the DNA code, offering the possibility to improve the immune system over what has evolved in a Darwinian fashion. In 2017 for the first time, CAR T cells were approved for the treatment of cancer. Today they are used worldwide in more than 15,000 patients and they offer the promise to move beyond cancer to other fields of medicine such as autoimmune disease and heart disease. Here I will discuss the promises and challenges faced by the evolving CAR T cell industry.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
CAR - T细胞的不可思议的发展:简史和未来的展望。
治愈癌症一直是医学界的圣杯之一。我要和你们分享的发现,CAR - T细胞,是一种很有前途的癌症治疗新形式,它提供了利用免疫系统治疗癌症的前景。CAR - T细胞是合成生物学进入医学实践的第一种形式。利用免疫系统对抗癌症是一个古老的想法。一个多世纪以前,细菌被磨碎并注射到晚期癌症患者体内,偶尔癌症会消失。然而,我们现在有了精确的基因编辑和基因插入工具,比如CRISPR/Cas9,可以重写DNA密码,从而提供了改善免疫系统的可能性,而不是按照达尔文的方式进化。2017年,CAR - T细胞首次被批准用于治疗癌症。如今,它们已在全球范围内用于超过15,000名患者,并有望从癌症扩展到其他医学领域,如自身免疫性疾病和心脏病。在这里,我将讨论不断发展的CAR - T细胞行业所面临的前景和挑战。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
KEIO JOURNAL OF MEDICINE
KEIO JOURNAL OF MEDICINE MEDICINE, RESEARCH & EXPERIMENTAL-
CiteScore
3.10
自引率
0.00%
发文量
23
期刊最新文献
Intravenous Regeneration-associated Cell Transplantation Enhances Tissue Recovery in Mice with Acute Ischemic Stroke. Warfarin Therapy and Percutaneous Left Atrial Appendage Closure for a Patient with Atrial Fibrillation and Antithrombin-III Deficiency. Efficacy of Cognitive Stimulation Therapy for Cognition in Patients with Vascular Cognitive Impairment: A Pilot Randomized Controlled Trial. Robotic Lobectomy with a Single Robotic Stapler from One 12-mm Port: A Multi-institutional Study. Incidence of Radiation-induced Nausea and Vomiting: A Prospective Single-institution Pilot Study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1